Trypanocidal Activity of Aziridinyl Nitrobenzamide Prodrugs (cid:1)
暂无分享,去创建一个
B. Hall | N. Helsby | S. Wilkinson | M. Taylor | C. Bot | Noosheen Bashir
[1] C. Bern,et al. Chagas disease in Spain, the United States and other non-endemic countries. , 2010, Acta tropica.
[2] Michelle R. Arkin,et al. Image-Based High-Throughput Drug Screening Targeting the Intracellular Stage of Trypanosoma cruzi, the Agent of Chagas' Disease , 2010, Antimicrobial Agents and Chemotherapy.
[3] K. Read,et al. Cross-Resistance to Nitro Drugs and Implications for Treatment of Human African Trypanosomiasis , 2010, Antimicrobial Agents and Chemotherapy.
[4] W. Denny,et al. A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors , 2010, Cancer Chemotherapy and Pharmacology.
[5] B. Hall,et al. Exploiting the Drug-Activating Properties of a Novel Trypanosomal Nitroreductase , 2009, Antimicrobial Agents and Chemotherapy.
[6] S. Montgomery,et al. An estimate of the burden of Chagas disease in the United States. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] Salah Ghabri,et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial , 2009, The Lancet.
[8] N. James,et al. A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase with CB1984. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[9] M. Bosenberg,et al. Nifurtimox Induces Apoptosis of Neuroblastoma Cells In Vitro and In Vivo , 2009, Journal of pediatric hematology/oncology.
[10] Longqin Hu,et al. Design of anticancer prodrugs for reductive activation , 2009, Medicinal research reviews.
[11] J. Samuelson,et al. Giardia, Entamoeba, and Trichomonas Enzymes Activate Metronidazole (Nitroreductases) and Inactivate Metronidazole (Nitroimidazole Reductases) , 2008, Antimicrobial Agents and Chemotherapy.
[12] D. Horn,et al. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes , 2008, Proceedings of the National Academy of Sciences.
[13] J. Boucher,et al. Metabolic activation of the antitumor drug 5-(Aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by NO synthases. , 2008, Chemical research in toxicology.
[14] G. Priotto,et al. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] F. Checchi,et al. Nifurtimox plus Eflornithine for Late-Stage Sleeping Sickness in Uganda: A Case Series , 2007, PLoS neglected tropical diseases.
[16] S. White,et al. Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954. , 2007, Journal of molecular biology.
[17] J. Wastling,et al. A Novel Giardia lamblia Nitroreductase, GlNR1, Interacts with Nitazoxanide and Other Thiazolides , 2007, Antimicrobial Agents and Chemotherapy.
[18] M. Zacks. Impairment of cell division of Trypanosoma cruzi epimastigotes. , 2007, Memorias do Instituto Oswaldo Cruz.
[19] J. Jannin,et al. The future of Chagas disease control. , 2006, Trends in parasitology.
[20] F. Checchi,et al. Three Drug Combinations for Late-Stage Trypanosoma brucei gambiense Sleeping Sickness: A Randomized Clinical Trial in Uganda , 2006, PLoS clinical trials.
[21] K. McCarten,et al. Antitumor Activity of Nifurtimox Observed in a Patient With Neuroblastoma , 2006, Journal of pediatric hematology/oncology.
[22] M. Taylor,et al. pTcINDEX: a stable tetracycline-regulated expression vector for Trypanosoma cruzi , 2006, BMC biotechnology.
[23] W. Wilson,et al. Aerobic 2- and 4-nitroreduction of CB 1954 by human liver. , 2005, Toxicology.
[24] D. Horn,et al. Tagging a T. brucei RRNA locus improves stable transfection efficiency and circumvents inducible expression position effects. , 2005, Molecular and biochemical parasitology.
[25] W. Denny,et al. Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase. , 2004, Journal of medicinal chemistry.
[26] W. Wilson,et al. 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT , 2004, British Journal of Cancer.
[27] Michael P Barrett,et al. The trypanosomiases , 2003, The Lancet.
[28] W. Denny,et al. Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy) , 2003, Journal of biomedicine & biotechnology.
[29] W. Denny,et al. Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation. , 2003, Chemical research in toxicology.
[30] Hilary G. Morrison,et al. Evidence for Lateral Transfer of Genes Encoding Ferredoxins, Nitroreductases, NADH Oxidase, and Alcohol Dehydrogenase 3 from Anaerobic Prokaryotes to Giardialamblia and Entamoebahistolytica , 2002, Eukaryotic Cell.
[31] D. Warhurst,et al. In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. , 2002, The Journal of antimicrobial chemotherapy.
[32] S. D. de Castro,et al. A critical review on Chagas disease chemotherapy. , 2002, Memorias do Instituto Oswaldo Cruz.
[33] D. Kerr,et al. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] T. C. Jenkins,et al. Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy. , 2000, Cancer research.
[35] Clifton E. Barry,et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis , 2000, Nature.
[36] R. Gazzinelli,et al. Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. , 1998, Molecular and biochemical parasitology.
[37] R. D. Conti,et al. Application of a multi-endpoint cytotoxicity assay to the trypanocidal compounds 2-propen-1-amine derivatives and determination of their acute toxicity , 1998 .
[38] A. Jaiswal,et al. Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. , 1997, Archives of biochemistry and biophysics.
[39] S. Martínez-Calvillo,et al. pRIBOTEX expression vector: a pTEX derivative for a rapid selection of Trypanosoma cruzi transfectants. , 1997, Gene.
[40] L. Amzel,et al. Molecular Basis of the Catalytic Differences among DT-diaphorase of Human, Rat, and Mouse* , 1997, The Journal of Biological Chemistry.
[41] F. Buckner,et al. Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase , 1996, Antimicrobial agents and chemotherapy.
[42] P. Biggs,et al. Identification, synthesis and properties of 5-(aziridin-1-yl)-2-nitro-4-nitrosobenzamide, a novel DNA crosslinking agent derived from CB1954. , 1993, Biochemical pharmacology.
[43] F. Friedlos,et al. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase. , 1992, Biochemical pharmacology.
[44] M. Miles,et al. A shuttle vector which facilitates the expression of transfected genes in Trypanosoma cruzi and Leishmania. , 1992, Nucleic acids research.
[45] F. Friedlos,et al. Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species. , 1991, Biochemical pharmacology.
[46] M. Miles,et al. Trypanosoma cruzi glycosomal glyceraldehyde‐3‐phosphate dehydrogenase does not conform to the ‘hotspot’ topogenic signal model. , 1990, The EMBO journal.
[47] H Hirumi,et al. Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. , 1989, The Journal of parasitology.
[48] U. Graf,et al. Genotoxicity testing of antiparasitic nitrofurans in the Drosophila wing somatic mutation and recombination test. , 1989, Mutagenesis.
[49] L. Filardi,et al. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. , 1987, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[50] L. C. Ferreira,et al. Mutagenicity of nifurtimox and benznidazole in the Salmonella/microsome assay. , 1986, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[51] R. Mason,et al. Reduction of nifurtimox and nitrofurantoin to free radical metabolites by rat liver mitochondria. Evidence of an outer membrane-located nitroreductase. , 1984, The Journal of biological chemistry.
[52] R. Mason,et al. Generation of free radicals induced by nifurtimox in mammalian tissues. , 1981, The Journal of biological chemistry.
[53] R. Mason,et al. Oxygen-sensitive and -insensitive nitroreduction by Escherichia coli and rat hepatic microsomes. , 1979, The Journal of biological chemistry.
[54] E. Grunberg,et al. Chemotherapeutic properties of heterocyclic compounds: monocyclic compounds with five-membered rings. , 1973, Annual review of microbiology.